



# Decision Analysis and Project & Portfolio Modelling for Drug Developers

Volt Pharma Associates 09.08.2017



#### SITUATION

A rapidly changing healthcare environment, new research discoveries, budgetary pressures, and uncertain clinical, regulatory and commercial success require organisations to make the right decisions earlier in the drug development process. Often these decisions are further complicated through multiple organisational objectives and the need to take individual project decisions in the context of the wider portfolio

Particularly when the number of projects grows beyond what is easily manageable, the efficiency of the resource allocation and the quality of the decision making process are likely to benefit from systematic use of Decision Analysis and Project & Portfolio Modelling.

Below are a list of questions we will help you to answer so that you can achieve the full potential of your portfolio and achieve your business goals:

#### > STRATEGIC

- When should we think about moving into new disease areas and exiting existing ones?
- What strategies should we adopt: License, Develop in-house, Acquire, Partner?
- How do we define a "valuable" project?

#### PORTFOLIO

- How does our portfolio of projects play out over time?
- How many projects do we need in each phase?
- How many launches will this give us, and do we need?
- Are adjustments needed to meet organizational goals?
- Are there any bottlenecks which need to be addressed, or gaps to be filled?
- How should we think about project priority, and trade-off of resources between projects?
- How can the pipeline delivery be sustained?
  - o Can we reduce attrition or cycle times?
  - o How can we better manage project life-cycles?
  - o Do we need increased input from Discovery, or licensing/partnership?

### DISEASE AREA

- If projects succeed (or fail), what should be done with linked projects?
  - o Management of clusters of projects within a single disease area
- How can the disease area portfolio be proactively managed?
  - o Scenario and "what if" analysis
  - o Identification of key decision points

## > RESOURCE

- Is the budget sufficient to meet goals, or will additional funds be needed?
- Given the current budget, how can it best be used?
- What is the demand on budget and resource over time? Are there looming squeezes, and when will the pressure be relieved?
- Can funding and resource be re-distributed between projects? If not, what impact does this have on decision-making and portfolio delivery?
- If budget is increased, which projects benefit most from additional funds? If budget is decreased, which projects suffer least from a reduction or delay in funding?

# > PROJECT

- What is the impact of adoption of "new development paradigms" on output and budget/resource demand?
  - o Should new ways of working be adopted?



- What are the risks, and how can they be mitigated?
- Which new projects should we bring into the portfolio and how should we prioritise?

# SERVICES BENEFITS

Volt Pharma Associates (VPA) can help you making informed decisions about robust project selection and resource allocation so that you can achieve the full potential of your portfolio. The VPA team consists of a pool of experts with many years of experience in drug development, portfolio management, project & portfolio modelling, decision analysis, project & programme management.

## Your benefits are:

- Clear strategy, easy to articulate
- Proactive management of the portfolio
- Better value, productivity and resource usage
- Better understanding of events and how to deal with them. Stay ahead of the game!

# ABOUT VOLT PHARMA ASSOCIATES

With the expertise of world-class BioPharmaceutical industry subject matter professionals, VPA put best practice to work for their clients, designing integrated innovative solutions for the complexities of a constantly changing life sciences ecosystem. Contact for further information:



Managing Partner: Claude Houet

**Title:** Head of Practice - Pharmaceutical and Life Sciences Industry

**Telephone:** +49 (0) 172 6340202 (mobile); +49 (0)761 600 69 355 (office)

Email: info@vpa.eu.com
Website: www.vpa.eu.com